Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Depigoid in Allergic Rhinitis and Asthma
NCT01591343Phase 2Terminated
- Sponsor
- LETI Pharma
- Start
- Jun 2012
- Primary completion
- Jul 2012
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Depigoid in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma, sponsored by LETI Pharma. Primary endpoint: Number of subjects who experienced at least one immediate or delayed systemic reaction of EAACI grade 2 or higher at 4 months. Started Jun 2012; status: terminated.
02
Drugs
Depigoid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on NCT01591343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591343.